

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
13 July 2006 (13.07.2006)

PCT

(10) International Publication Number
WO 2006/074025 A1

(51) International Patent Classification:

C07D 295/20 (2006.01) C07D 417/12 (2006.01)
 C07D 215/12 (2006.01) C07D 317/58 (2006.01)
 C07D 401/12 (2006.01) A61P 25/22 (2006.01)
 C07D 405/12 (2006.01) A61P 25/04 (2006.01)
 C07D 239/42 (2006.01) A61P 25/28 (2006.01)
 C07D 241/42 (2006.01) C07C 275/28 (2006.01)

(74) Agent: EVANS, Linda, S.; Patent Law Dept., Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, NJ 08933 (US).

(21) International Application Number:

PCT/US2005/047329

(22) International Filing Date:

29 December 2005 (29.12.2005)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/640,869 30 December 2004 (30.12.2004) US

(71) Applicant (for all designated States except US):
JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): APODACA, Richard [US/US]; 8448 Via Sonoma, #98, San Diego, CA 92037 (US). BREITENBUCHER, J., Guy [US/US]; 2433 North Summit Circle Glen, Escondido, CA 92026 (US). PATTABIRAMAN, Kanaka [IN/US]; 435 Paco Drive, Los Altos, CA 94024 (US). SEIERSTAD, Mark [US/US]; 9470 High Park Lane, San Diego, CA 92129 (US). XIAO, Wei [CN/US]; 4043 Carmel Springs Way, San Diego, CA 92130 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- with amended claims

Date of publication of the amended claims: 31 August 2006

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PIPERAZINYL AND PIPERIDINYL UREAS AS MODULATORS OF FATTY ACID AMIDE HYDROLASE

(57) Abstract: Compounds of formula (I) : wherein, Z is -N-or>CH; R¹ is -H or -C₁₋₄alkyl; Ar¹ is 2-thiazolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-primidinyl, 5-pyrimidinyl, or phenyl, each unsubstituted or substituted at a carbon ring member with one or two R^a moieties; Where each R^a moiety is independently selected from the group consisting of -C₁₋₄alkyl, -C₂₋₄alkenyl, -OH, -OC₁₋₄alkyl, halo, -CF₃, -OCF₃, -SCF₃, -SH, -S(O)₀₋₂C₁₋₄alkyl, -OSO₂C₁₋₄alkyl, -CO₂C₁₋₄alkyl, -CO₂H, -COC₁₋₄alkyl, -N(R^b)R^c, -SO₂NR^bR^c, -NR^bSO₂R^c, -C(=O)NR^bR^c, -NO₂, and -CN, wherein R^b and R^c are each independently -H or -C₁₋₄alkyl; and Ar² is defined in the claims are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat, e.g., anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders (such as multiple sclerosis).

WO 2006/074025 A1